Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01947374
Other study ID # 017-05-INR
Secondary ID
Status Completed
Phase Phase 3
First received February 4, 2012
Last updated April 11, 2017
Start date January 2010
Est. completion date January 2015

Study information

Verified date April 2017
Source Instituto Nacional de Rehabilitacion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase III, randomised controlled trial of matrix-encapsulated chondrocyte implantation procedure compared to the microfracture procedure in the repair of symptomatic cartilage lesions of the knee. Eligible patients were asked for informed consent preoperatively and randomised for chondrocyte implantation of microfractures. Those patients allocated to the chondrocyte implantation group will be harvested at time of first arthroscopic procedure and concurrent lesions were treated, as meniscus repair, ligament reconstruction, or malalignment corrected. The patients allocated to microfracture will be treated at the time of the only arthroscopic procedure. Both groups will have the same rehabilitation program. Prospective clinical, radiographic and magnetic resonance imaging will be performed as main outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Patients with symptomatic single chondral lesions of the knee from 1 to 4 cm2.

- Signed patient informed consent.

- Agree to adhere to rehabilitation protocol.

Exclusion Criteria:

- Inflammatory arthritis, septic arthritis, gout, pseudogout, Paget's disease, ochronosis, acromegaly, hemochromatosis, tumors, collagen mutations.

- Total meniscectomy

- Malalignment

- Evidence of osteoarthritis

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Matrix encapsulated chondrocyte implantation
Each implant contains 6,000,000 autologous chondrocytes.
Microfracture awl
Is an awl that allow perforation of the subchondral bone.

Locations

Country Name City State
Mexico National Institute of Rehabilitation Mexico City

Sponsors (2)

Lead Sponsor Collaborator
Instituto Nacional de Rehabilitacion National Council of Science and Technology, Mexico

Country where clinical trial is conducted

Mexico, 

References & Publications (3)

Ibarra C, Izaguirre A, Villalobos E, Masri M, Lombardero G, Martinez V, Velasquillo C, Meza AO, Guevara V, Ibarra LG. Follow-up of a new arthroscopic technique for implantation of matrix-encapsulated autologous chondrocytes in the knee. Arthroscopy. 2014 Jun;30(6):715-23. doi: 10.1016/j.arthro.2014.02.032. Epub 2014 Apr 18. — View Citation

Ibarra-Ponce de León JC, Velasquillo-Martínez MC, Izaguirre A, Villalobos-Córdova E, Masri M, Ibarra-Ibarra LG. [Cartilage repair: cell-based techniques]. Acta Ortop Mex. 2009 Jan-Feb;23(1):38-44. Review. Spanish. — View Citation

Masri M, Lombardero G, Velasquillo C, Martínez V, Neri R, Villegas H, Ibarra C. Matrix-encapsulation cell-seeding technique to prevent cell detachment during arthroscopic implantation of matrix-induced autologous chondrocytes. Arthroscopy. 2007 Aug;23(8):877-83. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary MRI T2 Mapping Special magnetic resonance imaging technique for measurement of collagen and water content, expressed in milliseconds. 24 months
Secondary Clinical evaluation Clinical assessment with validated knee scores, and adverse effects register are taken. 0, 10, 30 days; 3, 6, 9 ,12, 24, 36 months
See also
  Status Clinical Trial Phase
Completed NCT02673905 - Clinical Trial for the Regeneration of Cartilage Lesions in the Knee N/A
Completed NCT01503970 - Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration Phase 1/Phase 2

External Links